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Prime boostA new vaccination strategy for dengue virus (DENV) was evaluated in rhesus macaques by priming with
tetravalent puriﬁed inactivated virus (TPIV) or tetravalent plasmid DNA vaccines expressing the structural
prME gene region (TDNA) then boosting 2 months later with a tetravalent live attenuated virus (TLAV)
vaccine. Both vaccine combinations elicited virus neutralizing (N) antibodies. The TPIV/TLAV combination
afforded complete protection against DENV 3 challenge at month 8. In a second experiment, priming with
TPIV elicited N antibodies against all four serotypes (GMT 1:28 to 1:43). Boosting with TLAV led to an
increase in the GMT for each serotype (1:500 to 1:1200 for DENVs 1, 3, and 4, and greater than 1:6000 for
DENV 2), which declined by month 8 (GMT 1:62 for DENV 3, 1:154 for DENV 1, 1:174 for DENV 4, and 1:767
for DENV 2). After challenge with each one of the four DENV serotypes, vaccinated animals exhibited no
viremia but showed anamnestic antibody responses to the challenge viruses.
Published by Elsevier Inc.Introduction
The dengue viruses (DENVs), comprised of four distinct serotypes,
DENVs 1, 2, 3, and 4, in the family Flaviviridae, are transmitted to
humans by Aedes aegypti mosquitoes resulting in an estimated 100
million infections annually in the tropics and subtropics (Monath,
1986). Most dengue infections are asymptomatic or result in
uncomplicated dengue fever (DF), a mild to moderate acute febrile
illness. Because immunity following infection is serotype speciﬁc,
individuals remain at risk for secondary infection from other
serotypes. A small but signiﬁcant number of individuals develop
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS),
which are severe, sometimes life-threatening illnesses. The risk for
DHF and DSS is greater following a second dengue infection (Halstead,
1988), although the pathogenesis is not fully understood. While
serotype-speciﬁc virus neutralizing antibodies directed against the
virion envelope (E) antigen are associated with protection (Kaufman
et al., 1987), non-neutralizing, cross-reactive antibodies appear to
mediate the infection of Fc receptor bearing cells, e.g., monocytes and
macrophages, leading to higher viremia and more severe disease
(Halstead, 1988) underscoring the need for a vaccine that protects
against all four DENV serotypes.
Most recent efforts to develop a dengue vaccine have focused on
live attenuated viruses (LAVs) (Bhamarapravati, Yoksan, 1997).M. Simmons),
h@us.army.mil (J. Lynch),
Inc.However, the safety and efﬁcacy of these products has yet to be
demonstrated (Sabchareon et al., 2002). Unpredictable interactions
among the four virus serotypes in tetravalent LAV (TLAV) formula-
tions have historically made it difﬁcult to achieve a vaccine that is
both satisfactorily attenuated and highly immunogenic. This was
demonstrated by signiﬁcant dengue-like illness seen in clinical trials
of one candidate dengue TLAV vaccine where an under-attenuated
DENV 3 component in the tetravalent formulation was the apparent
cause of the reactogenicity (Kitchener et al., 2006), which effectively
halted the further clinical development of that product.
Three other TLAV vaccine candidates are currently in clinical trials.
One of these vaccines is attenuated by serial passage of wild-type
viruses in PDK cells followed by production in fetal rhesus lung (FRhL)
diploid cells (Halstead andMarchette, 2003; Eckels et al., 2003; Sun et
al., 2003; Sun et al., 2009). The other two are genetically engineered
chimeras, with the dengue structural genes expressed from an
infectious clone of yellow fever virus 17D vaccine (Guirakhoo et al.,
2006), or an infectious clone of DENV 4 containing attenuating
mutations in the 3′ non-coding region of the viral genome (McArthur
et al., 2008; Durbin et al., 2006a,b), produced in Vero cells. While all
three of these products have good safety proﬁles, it has proven
difﬁcult to achieve tetravalent virus neutralizing antibody responses
after one dose of vaccine, possibly because some virus serotypes
replicate more efﬁciently so as to be dominant over or interfere with
other serotypes in the tetravalent mixture. Evidence for cross serotype
interference can also be seen in rhesus monkeys (Guy et al., 2009).
Although serotype dominance or interference is less apparent after
booster immunizations, the need for multiple doses and long
immunization schedules limit the suitability of these products as
Fig. 1. DENV neutralizing antibody responses in rhesus macaques vaccinated with
combinations of tetravalent live attenuated virus (TLAV), tetravalent puriﬁed
inactivated virus (TPIV), and tetravalent DNA (TDNA) vaccines and then challenged
at month 8 with live, non-attenuated DENV 3. Reciprocal geometric mean neutralizing
antibody PRNT50 titers are presented for all time points.
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non-dengue ﬂaviviruses Japanese encephalitis or yellow fever were
shown to demonstrate secondary type immune responses after
primary vaccination with DEN LAV vaccines. (Kanesa-Thasan et al.,
2003). An earlier monovalent DENV 2 LAV vaccine candidate was also
found to be more immunogenic in yellow fever immune subjects
(Scott et al., 1983), probably due to increased vaccine viremia
(Bancroft et al., 1981). This suggests that immunological priming,
even with heterologous antigen, can signiﬁcantly alter the host's
immune responses to DEN LAV vaccines.
In addition to the TLAV vaccines currently in advanced clinical
trials, there are other DENV vaccine candidates in earlier stages of
testing, including a chimeric LAV vaccine in an attenuated DENV 2
background (Huang et al., 2003), a puriﬁed inactivated whole virus
(PIV) vaccine (Putnak et al., 2005), a recombinant subunit vaccine
based on the aminoterminal 80% of E protein (Putnak et al., 2005), a
recombinant subunit vaccine based on E domain III (Simmons et al.,
2001), and a DNA vaccine expressing the prME structural gene region
(Simmons et al., 2001). One advantage of non-replicating vaccines is
that they might immunize more quickly and exhibit less serotype
dominance or interference than LAV vaccines, although some might
be less effective at eliciting cell-mediated immune responses and at
conferring long-term immunity. Alternatively, it might be possible to
use some combination of live and non-replicating vaccines to achieve
a more balanced immune response in a shorter period of time. The
idea of priming and boosting with different vaccines has previously
been tested experimentally for immunizing against HIV (Barnett et al.,
1997) and malaria (Sedegah et al., 1998).
In the present study, we tested a prime boost approach for dengue
in rhesus macaques by priming the animals with either TPIV or TDNA
vaccines followed by boosting with a TLAV vaccine. The vaccinated
animals were then challenged with near wild-type strains of DENV to
determine if they were protected. Although dengue infection in the
rhesus model is clinically inapparent, dengue non-immune animals
become viremic when challenged; therefore, in this model viremia
serves as a surrogate for human infection, and as a way for measuring
the protective efﬁcacy of DENV vaccine candidates (Sun et al., 2006).
We found that animals primed with non-replicating vaccines
developed mainly low titered virus neutralizing antibodies and also
non-neutralizing antibodies, which could be measured by ELISA. After
boosting with the TLAV vaccine, the animals exhibited a secondary
type immune response with higher titered and more broadly cross
serotype-reactive neutralizing antibodies than were seen after
priming or after a single dose of TLAV vaccine. Animals that received
the TPIV/TLAV prime boost vaccine were completely protected
against viremia after virus challenge. These results suggest that a
prime boost vaccination strategy might be effective for protecting
humans against dengue.
Results
Non-replicating tetravalent DENV vaccines primed rhesus maca-
ques for an immune response to a tetravalent live attenuated virus
(TLAV) vaccine.
An initial experiment was performed in 16 ﬂavivirus naïve rhesus
macaques to determine the most effective priming vaccine, dengue
tetravalent DNA (TDNA) or tetravalent PIV (TPIV) vaccine. Animals
were randomly assigned to one of four groups with each group
containing 4 animals, and inoculated with either two doses of TDNA
vaccine (Group 1), one dose of TPIV vaccine (Group 2), or for
comparison, with one dose of TLAV vaccine (Group 3). An unvacci-
nated control group received phosphate-buffered saline only (Group
4). Two months later, all animals except the saline controls were
boosted with one dose of the TLAV vaccine. Measurement of virus
neutralizing (N) and total antibody titers against all four DENV
serotypes after vaccination and measurement of serum viremia aftermonovalent challenge with a near wild-type strain of DENV 3 were
used to evaluate the more effective prime boost vaccine combination.
Antibody responses to vaccination
After primary vaccination, all groups except the saline control
made antibodies to all four DENV serotypes measured by ELISA (data
not shown) and virus plaque reduction neutralization test (PRNT50)
(Fig. 1) and remained positive for virus N antibodies 30 and 60 days
after primary vaccination. The N antibody geometric mean titers
(GMTs) for serotype 2 were higher than for the other serotypes. After
boosting with the TLAV vaccine, the N antibody GMTs for all serotypes
increased in all groups, reaching a peak 1 month later, at which time
the highest N antibody GMTs were against DENV 2 and DENV 4. The N
Fig. 2. Anti-DENV 3 IgG antibody responses measured by ELISA on the day of challenge
and protection from viremia after challenge. Bars indicate reciprocal geometric mean
endpoint titers (GMT) measured by ELISA (≥0.1 OD), and circles indicate mean days of
viremia measured by virus ampliﬁcation in Vero cells followed by IFA.
282 M. Simmons et al. / Virology 396 (2010) 280–288antibody titers then declined sharply over the next 2 months and
more gradually thereafter until administration of the challenge virus
at month 8. On the day of challenge, all groups remained antibody
positive, with Group 2 (TPIV/TLAV) exhibiting the highest total and N
antibody titers and with the highest N antibody titers being against
DENV 2.
Responses to monovalent wild-type DENV 3 challenge
To assess protection, a near wild-type isolate of DENV 3 was
chosen because the lowest virus N antibody titers in all groups were
against serotype 3. The DENV 3 challenge virus was administered to
all animals including the saline controls, and sera were collected for
10 consecutive days for measuring viremia. The post-challenge
viremia results are shown in Table 1. Group 4 (saline) exhibited on
average 5 days of viremia, whereas Group 1 (TDNA/TDNA/TLAV)
exhibited 1.5 days of viremia on average and Group 2 (TPIV/TLAV)
and Group 3 (TLAV/TLAV) exhibited no viremia after the virus
challenge. In this experiment, there was a correlation between higher
total anti-DENV 3 Ig titers on the day of challenge measured by ELISA
and protection (Fig. 2). After the virus challenge, N antibody GMTs to
all serotypes increased in all vaccine groups, with a 50-fold increase in
anti-DENV 3 N antibody titer for the animals in Group 1 (TDNA/
TDNA/TLAV), a 5-fold increase for the animals in Group 2 (TPIV/
TLAV), and a 10-fold increase for the animals in Group 3 (TLAV/TLAV)
(Fig. 1). Based on these results, a second experiment was performed to
determine whether priming with a TPIV vaccine followed by boosting
with a TLAV vaccine can confer protection against all four DENV
serotypes.
DEN TPIV and DEN TLAV vaccines used in a prime boost vaccine
combination protected rhesus macaques against challenge with all four
DENV serotypes
For this experiment, 32 ﬂavivirus naïve animals were randomly
assigned to two cohorts of 16 animals each. The ﬁrst cohort was
vaccinated with TPIV vaccine followed 2 months later by TLAVTable 1
Viremia in rhesus macaques immunized with combinations of tetravalent live attenuated v
vaccines and then challenged with live, non-attenuated DENV 3.
⁎Filled black squares show the days after challenge that dengue virus was detected in seravaccine. The second (control) cohort was mock vaccinated with
phosphate-buffered saline. At month 8, both the vaccine and the
control cohorts were challenged with low passage, near wild-type
DEN viruses, with 4 vaccinated and four control animals per group
receiving either DENV 1, 2, 3, or 4, one challenge virus administered
per group. Sera were collected at intervals to measure antibody
responses to vaccination and challenge, and daily for 10 days after
both TLAV vaccination and virus challenge to measure viremia.Antibody responses after vaccination with TPIV and boosting with
TLAV vaccine
The results in Fig. 3 show that after primary vaccination with
TPIV, all animals had N antibodies to all four DENV serotypes.
Although the GMTs were low they were similar for all serotypes.irus (TLAV), tetravalent puriﬁed inactivated virus (TPIV), and tetravalent DNA (TDNA)
by ampliﬁcation in Vero cells followed by detection of virus-infected cells using IFA.
Fig. 3. DENV neutralizing antibody responses in rhesus macaques primed with tetravalent puriﬁed inactivated virus (TPIV) vaccine (Day 0), boosted with tetravalent live attenuated
virus (TLAV) vaccine (Day 60), and then challenged at month 8 with live, non-attenuated DENV 1, DENV 2, DENV 3, or DENV 4. Reciprocal geometric mean neutralizing antibody
PRNT50 titers are presented from day 0 until the day of challenge, day 240.
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vaccination given at month 2 and peaked between study day 90
and day 120, with the highest GMT achieved for DENV 2 (1:6000)
and lower GMTs ranging from 1:500 to 1:1200 for the other
serotypes. The GMTs for all serotypes then declined at variable
rates, with the steepest decline in titer occurring within one to
2 months after peaking, followed by a more gradual decline to the
day of challenge, similar to what was seen in the ﬁrst experiment.
On the day of challenge (month 8), the N antibody GMTs were 1:62
for serotype 3, 1:154 for serotype 1, 1:174 for serotype 4, and 1:767
for serotype 2.Viremia responses after TLAV vaccination and tetravalent wild-type
DENV challenge
While priming with TPIV vaccine did lead to better immune
responses to the TLAV vaccine, it did not enhance the replication of
any of the vaccine viruses leading to detectable viremia (data not
shown). In order to determine if the vaccinated animals were
protected against all four DENV serotypes, both vaccinated and
control (mock vaccinated) cohorts were challenged with near wild-
type challenge viruses, with groups of 4 vaccinated and 4 control
animals each receiving a different challenge virus, DENV 1, 2, 3, or 4.
The post-challenge viremia results are shown in Table 2. In the mock
(PBS) vaccinated cohort, all animals challenged with each DENV
serotype became viremic, thus demonstrating a successful challenge
for each serotype. The animals challenged with DENV 4 exhibited the
shortest duration of viremia with a mean of 2.75 days, whereas the
animals challenged with DENV 1, DENV 2, or DENV 3 exhibited 4 to 5
mean days of viremia, consistent with previous rhesus challenge
experiments (Simmons and Putnak, unpublished results). In contrast,
in the vaccinated cohort, there was no detectable viremia with any of
the challenge virus serotypes. There were, however, anamnestic
antibody responses observed in most vaccinated animals after the
virus challenge, with increases in N antibody titers against all
serotypes and an increase in total antibody titers against DENV 2,
DENV 3, and DENV 4 (Fig. 4).Discussion
It has proven very difﬁcult and costly to develop tetravalent
dengue vaccine candidates that immunize and confer both immediate
and long-term immunity to all four virus serotypes with a minimum
of vaccine-associated adverse effects. Following primary vaccination
of ﬂavivirus naïve subjects in clinical trials with some tetravalent live
attenuated virus (TLAV) vaccine formulations, protective virus
neutralizing antibodies against some serotypes are very low or
undetectable, suggesting that those serotypes replicate and immunize
poorly. In contrast, other virus serotypes appear to dominate the
immune response and sometimes cause viremia, which may lead to
increased vaccine reactogenicity seen as dengue-like illness (Kitch-
ener et al., 2006). Although a second dose of TLAV vaccine generally
leads to improved tetravalent seroconversion rates and higher virus
neutralizing antibody titers with reduced reactogenicity, it appears
that this must be administered 6 months or longer following primary
vaccination in order to be most effective. Non-replicating tetravalent
dengue vaccines may exhibit less serotype dominance and vaccine-
associated adverse effects and allow for the use of shorter time
intervals between primary and booster vaccinations. However, such
vaccines may not be as effective as TLAV vaccines at conferring long-
term immunity. Therefore, in this study an alternative strategy for
vaccinating against dengue was tested in the rhesus macaque animal
model. This involved priming the animals with a non-replicating
vaccine, either a tetravalent puriﬁed inactivated virus (TPIV) or a
tetravalent plasmid DNAs expressing the prME structural gene region
(TDNA), followed by boosting with a tetravalent live attenuated virus
(TLAV) vaccine. The aims of this study were threefold: (i) to
demonstrate that priming with a non-replicating vaccine followed
by boosting with a TLAV vaccine is able to elicit high titered virus
neutralizing (N) antibodies and confer protection against all four
DENV serotypes; (ii) to demonstrate that a heterologous prime boost
vaccination strategy has a low risk for eliciting vaccine-related
adverse events and might even reduce the risk for reactogenicity by
moderating the replication of under-attenuated viruses in a tetrava-
lent LAV vaccine; and (iii) to demonstrate the feasibility of a
compressed immunization schedule (2–3 months vs. 6–7 months),
Table 2
Viremia in rhesus macaques immunized with tetravalent puriﬁed inactivated virus (TPIV) vaccine, boosted with tetravalent live attenuated virus (TLAV) vaccine, and then
challenged with live, non-attenuated strains of DENV 1, 2, 3, or 4.
⁎Filled black squares show the days after challenge that dengue virus was detected in sera by ampliﬁcation in Vero 81 cells followed by detection of virus-infected cells by IFA.
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immunity than can be achieved with existing TLAV vaccine
candidates.
An initial experiment was performed in rhesus macaques to
determine whether TPIV or TDNA vaccine was more effective at
priming for a booster response to a TLAV vaccine administered
2 months later. After priming with two doses of TDNA, one dose of
TPIV, or one dose of TLAV vaccine, the seroconversion rates and virus
N antibody titers against each serotype measured by PRNT were
comparable among groups, except for much higher DENV 2 N
antibody titers in the TLAV group. Following boosting with the TLAV
vaccine, the kinetics of the anamnestic N antibody response was
similar for all groups. The highest N antibody GMTs were against
DENV 2 followed by DENVs 4, 1, and 3. Measurement of total DENV 3
IgG titers by ELISA on the day of challenge showed that the TPIV/TLAV
group had the highest titer followed by the TLAV/TLAV group, while
the TDNA/TDNA/TLAV group had the lowest total IgG titer. Becausethe DENV 3 N antibody titers were lower than those for the other
serotypes in all three immunization regimens, this virus was chosen
for the challenge.
After DENV 3 challenge, complete protection against viremia was
seen in groups that received the TPIV/TLAV and TLAV/TLAV
combinations. Breakthrough viremia was detected in the TDNA/
TDNA/TLAV group, although it was reduced in duration compared to
the mock-vaccinated controls. After the DENV 3 challenge, all groups
including the TLAV/TLAV group exhibited anamnestic N antibody
increases for all serotypes. Not surprisingly, the greatest increase in N
antibody titer after challenge was seen in the TDNA/TDNA/TLAV
group, with the greatest fold increase in titer and the highest absolute
titer against DENV 3, consistent with the breakthrough viremia
observed in those animals. It is unclear why the TDNA/TDNA/TLAV
combination provided incomplete protection from challenge. Priming
by TDNA vaccine required two doses vs. one dose for TPIV. It is
possible that at least some epitopes important for protection were
Fig. 4. Anamnestic anti-DENV antibody responses in vaccinated rhesus macaques
measured by ELISA and PRNT using sera collected 2 weeks after tetravalent DENV
challenge. Blue bars indicate reciprocal geometric mean endpoint titers (GMT)
measured by ELISA (≥0.1 OD), and brown bars indicate reciprocal geometric mean
50% plaque reduction neutralizing antibody titers (GMT PRNT50) measured by PRNT.
An anamnestic antibody response was deﬁned a ≥4-fold increase in titer.
285M. Simmons et al. / Virology 396 (2010) 280–288either not correctly expressed or presented by this vaccine. Somewhat
surprisingly, the best correlate of protection against viremia in this
experiment was the total anti-DENV 3 IgG antibody measured by
ELISA on the day of challenge, rather than the neutralizing antibody
titer.
Based on results from the ﬁrst experiment, the TPIV/TLAV prime
boost vaccine combination was tested for the ability to confer
protection against viremia after challenge with wild-type strains of
all four DENV serotypes. Similar to the ﬁrst experiment, animals were
primed with one dose of TPIV, boosted with TLAV 2 months later, and
then challenged at month 8, with four animals receiving each
challenge virus serotype. After the administration of the TPIV vaccine,
the animals developed low but measurable N antibody titers against
each serotype demonstrating successful priming. After the TLAV
booster, the N antibody titers against each serotype increased more
than 10-fold, indicating strong anamnestic antibody responses.
Importantly, after the TLAV booster no vaccine-associated viremia
was detected for any serotype nor did the animals show any other
adverse effects, suggesting that TPIV priming was safe. N antibody
titers declined sharply at ﬁrst and then more gradually to the day of
challenge (month 8) at which time the highest N antibody titers were
against DENV 2 (1:767) followed by DENV 4 (1:174), DENV 1 (1:154),
and DENV 3 (1:62). In comparison, the total DENV IgG titers on the
day of challenge were highest for DENV 1 and DENV 2, followed by
DENV 4 and DENV 3. This difference between N and total antibody
titers among serotypes may have been due to the greater serotype
cross-reactivity of total IgG antibodies compared with N antibodies,
which tend to be more serotype speciﬁc. After the virus challenge,
there was complete protection against viremia from all four serotypes.
There were, however, strong anamnestic N antibody responses to
three of the four challenge viruses as shown in Fig. 3, with
approximately 8- to 14-fold increases in N antibody titers for DENVs
3, 4, and 1 but only about a threefold increase in titer for DENV 2,
possibly indicating near sterile immunity to DENV 2. In comparison,
total antibody titers, which were higher prior to challenge, did not
increase as much after challenge, with only two- to threefold
increases for DENVs 2, 3, and 4 and no measurable increase for
DENV 1.
These two experiments clearly demonstrated that rhesus maca-
ques could be successfully immunized and protected against all four
DENV serotypes using TPIV vaccine followed by TLAV vaccine in a
prime boost vaccination strategy. Low but measurable titers of Nantibody were elicited against each DENV serotype by primary
vaccination with TPIV demonstrating successful priming. However,
the presence of these virus N antibodies after priming apparently did
not inhibit replication of the TLAV vaccine enough to prevent
successful boosting, as evidenced by strong anamnestic N antibody
responses following TLAV administration. Although it could not be
demonstrated in these experiments, it is possible that low titered
virus neutralizing antibodies may be able to modulate the replication
of under-attenuated strains present in TLAV vaccine formulations,
thereby reducing vaccine reactogenicity. It is also notable that non-
neutralizing, presumably serotype cross-reactive antibodies generat-
ed in response to primary vaccination did not enhance the replication
of the attenuated vaccine viruses to the point of viremia.
Although the signiﬁcance of the immune-dominance of DENV
serotype 2 in terms of the N antibody response is unclear, the uniform
development of N antibodies against all four DENV serotypes within
1month after the TLAV booster, without evidence for vaccine-induced
viremia, further demonstrated that priming with non-replicating
vaccine was effective and suggests that protective immunity can be
achieved safely and rapidly by heterologous prime boost vaccination.
Arguably, however, TLAV vaccine alone, when two doses were
administered 2 months apart, was also able in a short period of time
to elicit moderate to high titered N antibodies against all four DENV
serotypes in the rhesus model, in contrast to the requirement for a
longer time interval between doses for effective immunization of
humans. This result suggests some shortcomings to the use of rhesus
macaques for predicting the outcome of vaccination in humans.
Nevertheless, viremia in rhesus macaques is the best animal model for
dengue infection currently available, and the results clearly demon-
strate that animals vaccinated with TPIV followed by TLAV vaccine
were completely protected against viremia after challenge 8 months
later with near wild-type DENV strains representing each serotype.
The reason for the challenge breakthrough seen in the ﬁrst
experiment with DENV 3 viremia in animals vaccinated with the
TDNA/TDNA/TLAV combination is unclear. The low DENV 3 N
antibody GMT (1:41) at the time of challenge might have been a
plausible explanation except that the TLAV/TLAV group had a
similarly low DENV 3 GMT (1:47), yet that group was completely
protected. Interestingly, the animals in the TDNA/TDNA/TLAV group
also had the lowest total DENV IgG antibody titers at month 8, and
there was a correlation between total DENV IgG titers at the time of
challenge and protection against viremia. Therefore, it is possible that
non-neutralizing antibodies may also play an important role in
protective immunity, perhaps through complement mediated lysis of
virus and virus-infected cells, or antibody-dependent cell-mediated
cytotoxicity (ADCC), which is difﬁcult to measure in vitro.
In future studies, it will be important to further deﬁne the
correlates of immunity to DENV as well as test the safety and
immunogenicity of heterologous prime boost vaccine approaches in a
Phase 1 clinical trial.
Materials and methods
Viruses
Cell culture supernatant harvested from Vero cells infected with
DENV 1 (West Pac 74), DENV 2 (S16803), DEN 3 (CH53489), and DEN
4 (341750) was used as virus stock for the plaque reduction
neutralization test (PRNT) and to prepare antigen for the ELISA.
Plaque-reduction neutralization assay
Plaque-reduction neutralization tests (PRNTs) were performed to
measure DENV neutralizing antibodies, using amethodmodiﬁed from
that originally described (Russell et al., 1967). Vero cell monolayers
were seeded in six-well plates (Falcon; Becton Dickinson, Lincoln
286 M. Simmons et al. / Virology 396 (2010) 280–288Park, NJ) and incubated at 37 °C in a CO2 incubator. Sera from
immunized rhesus macaques were tested using serial twofold
dilutions starting at 1:10 to 1:640 or as required to reach an endpoint.
The serum dilutions were mixed with each parental DENV serotype to
obtain approximately 50 plaque forming units (PFU) per 0.2 ml,
incubated at 37 °C for 30 min, then inoculated onto duplicate wells
overlayered with nutrient agarose (EMEM, 2% FBS, 1% agarose).
Plaques were visualized on day 6 by staining with 0.02% neutral red in
Hank's balanced salt solution. The number of plaques reported for
each serum dilution was the average of the duplicate wells. The
percent reduction in plaques was calculated by comparison of the
results obtained with control sera from unimmunized rhesus
macaques. The neutralization titer was the test serum dilution at
which 50% plaque reduction occurred (PRNT50 titer) determined by
probit analysis.
Enzyme-linked immunosorbent assay
Antigen was prepared by centrifugation (27,000 rpm at 20 °C) of
DENV-infected and -uninfected Vero cells for 2 h. Pellets were
resuspended in PBS and pelleted again in 10% glycerol at 32,000 rpm
for 2 h at 20 °C. Puriﬁed virions and control antigenwere resuspended
in PBS and stored at −20 °C until used. The analysis of sera from
immunized rhesus macaques for DENV-2 antibodies was carried out
as previously described (Simmons et al., 2006). Brieﬂy, microtiter
plate wells were coated with puriﬁed DENV 2 virions in PBS at 4 °C
overnight followed by blocking with 5% non-fat dry milk in PBS/0.01%
Tween 20 for 1 h at 37 °C. Plates were then incubated with the test
sera at twofold dilutions starting at 1:100 in blocking buffer for 1 h at
37 °C. The secondary antibody was peroxidase-conjugated goat anti-
human IgG (Kirkegaard & Perry, Gaithersburg, MD) diluted in
blocking solution and incubated for 1 h at 37 °C. The 2.2′ azinodi
[3ethyl benzthiazoline sulfonate (6)] (ABTS) peroxidase substrate
system (Kirkegaard & Perry) was used to visualize dengue virus-
speciﬁc antibody. Assays were performed in duplicate with a positive
and negative control on every plate. The net optical density (OD)
values were determined by subtracting the absorbance of test serum
with negative control antigen from the absorbance of test serum with
the DENV antigen. Endpoint dilution titers were determined by the
dilution at which the OD value was at ≥0.10.
Preparation and administration of live attenuated virus (LAV) vaccines
Production and testing of LAV vaccine candidates have previously
been described in detail (Eckels et al., 2003; Sun et al., 2003, 2009).
Brieﬂy, the viruses were isolated from viremic sera from clinical DEN
cases and attenuated by serial passage in primary dog kidney (PDK)
cells, 6 to 50 PDK passages depending on the virus serotype and the
vaccine formulation (Halstead and Marchette, 2003). Following PDK
passage, the vaccines were ﬁnished by three additional passages in
diploid fetal rhesus lung-2 (FhRL 2) cells to produce the master and
production seeds and the vaccines. The candidate monovalent vaccine
viruses were tested individually and demonstrated to elicit signiﬁ-
cantly reduced viremia compared to the wild-type parental isolated
when administered to rhesus monkeys (Eckels et al., 2003). The
monovalent LAV vaccines were formulated with excipients, 50 μg/ml
neomycin sulfate, 5.5% lactose, and 1.9% human serum albumin as
stabilizer, bottled, freeze dried, and stored at −20 C. Prior to
immunizations, each monovalent vaccine was rehydrated with sterile
water for injection, and syringe mixed to produce tetravalent
formulations, then administered to the animals by subcutaneous
(SC) inoculation into the loose skin of the upper back at a dose of 5
log10 pfu per serotype.
The tetravalent LAV (TLAV) formulation used for the ﬁrst rhesus
experiment consisted of DENV 1 (West Pac 74, 45AZ5, PDK 20), DENV
2 (S16803, PDK 50), DENV 3 (CH53489, PDK 20), and DENV 4(341750, PDK 6). The TLAV formulation for the second experiment
was the same except that DENV 1 PDK 20 was replaced by DENV 1
PDK 27. This substitution was made necessary because the DENV 1
PDK 20 vaccine was re-derived by RNA transfection of FRhL cells and
the re-derived vaccine was genetically less stable than the original
DENV 1 PDK 20 vaccine used in the ﬁrst experiment.
Preparation and administration of puriﬁed inactivated virus
(PIV) vaccine
The TPIV vaccine was prepared from DENVs (DENV 1West Pac 74,
DENV 2 S16803, DENV 3 CH53489, DENV 4 341750) propagated in
Vero cells. For the second experiment, DENV 4 strain 341750 was
substituted with strain TVP360 because TVP 360 was originally used
for the PIV production seed based on its ability to reach higher titers in
the Vero cell substrate. Virus in the culture supernatant was
concentrated by tangential ﬂow ultraﬁltration using a 100-kDa screen
channel membrane (Filtron, Inc.), puriﬁed by sucrose gradient
ultracentrifugation, and inactivated with formalin as originally
described (Putnak et al., 1996). Monkeys were inoculated intramus-
cularly by needle and syringe in the upper arm (deltoid) with 4 μg
(1 μg/serotype) of the TPIV formulation adjuvanted with 0.01%
aluminum hydroxide (alum).
Preparation and administration of plasmid DNA vaccine
TDNA vaccines were prepared as previously described (Kochel et
al., 1997). The vaccine constructs contained the DENV pre membrane
(M) and full-length envelope (E) genes cloned into plasmid vector
pVR1012 (Vical, San Diego, CA). The DENV 1 vaccine construct
contained sequences from the Western Paciﬁc 74 (West Pac 74)
strain, whereas the plasmid constructs for DENVs 2, 3, and 4 contained
sequences from near wild-type Philippine strains. The DENV 2
construct was modiﬁed by replacing the DENV transmembrane and
cytoplasmic sequences with those of the mouse lysosome-associated
membrane protein (LAMP) at the carboxy terminus of the E protein
(D2MEL) (Raviprakash et al., 2001, 2003). Animals received 5 mg
(1.25 mg/serotype) of TDNA vaccine per dose administered intra-
muscularly in the upper arm (deltoid), using the needle free Biojector
system (Raviprakash et al., 2003).
Animal immunizations and virus challenge
For the ﬁrst experiment, 16 healthy, ﬂavivirus naïve, Indian origin
rhesusmacaques (Macaca mulatta) were randomized into four groups
(n=4 animal/group). Group 1 was primed with two doses of the
TDNA vaccine on day−30 and day 0, group 2 was primed once with
TPIV vaccine on day 0, and group 3 was primed once with the TLAV
vaccine on day 0. Groups 1–3were then boostedwith TLAV vaccine on
day 60. Group 4 served as a control group and received saline only on
days 0 and 60. Six months after, the TLAV booster the animals were
challenged with live near wild-type DENV 3 (CH53489) PDK 0.
For the second experiment, 32 healthy, ﬂavivirus naïve rhesus
macaques were divided into two groups of 16 animals each. Sixteen
animals received the TPIV vaccine on day 0 and the TLAV vaccine on
day 60. The remaining 16 animals served as a control group and
received saline on days 0 and 60. Six months after, the last
immunization paired groups of four vaccinated and four control
animals were challenged with each of the four dengue viruses, with
one group challengedwith DENV 1, another DENV-2, another DENV-3,
and the ﬁnal group receiving DENV-4. DENV challenges were
administered by subcutaneous injection in the upper arm using 5
log10 pfu of DENV 1 (West Pac 74), DENV 2 (S16803), DEN 3
(CH53489), or DEN 4 (341750), derived from wild-type virus isolates
passaged only 3–4 times in Vero cells to make challenge virus stocks.
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The presence of virus in serum samples collected daily for 10
consecutive days after virus challenge was detected by incubation on
Vero cell monolayers followed by immunoﬂuorescent antibody (IFA)
assay. Brieﬂy, Vero 81 cells (ATCC) were propagated in 25 cm2 ﬂasks
(T25) with EMEM, non-essential amino acids (BioWhittaker), 10%
heat-inactivated FBS, and penicillin/streptomycin. Duplicate ﬂasks
were inoculated with 0.3 ml of a 1:2 dilution of each post-challenge
serum sample and incubated at 37 °C for 14 days, with a complete
media change on day 7. Cells from each ﬂask were harvested by
scraping, washed with PBS, and spotted in duplicate onto immuno-
ﬂuorescence slides. DENV-infected cells were detected by staining
with anti-DENV serotype-speciﬁc monoclonal antibodies as well as
HMAF followed by FITC-conjugated goat anti-mouse Ig. The cell
ﬂuorescence was scored as positive (+) or negative (−) compared to
uninfected control cells.
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